UBS Group’s Atea Pharmaceuticals AVIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $394K | Buy |
109,424
+45,856
| +72% | +$165K | ﹤0.01% | 5022 |
|
|
2025
Q1 | $190K | Sell |
63,568
-9,345
| -13% | -$27.9K | ﹤0.01% | 5349 |
|
|
2024
Q4 | $244K | Sell |
72,913
-5,478
| -7% | -$18.4K | ﹤0.01% | 5140 |
|
|
2024
Q3 | $263K | Buy |
78,391
+6,812
| +10% | +$22.8K | ﹤0.01% | 4511 |
|
|
2024
Q2 | $237K | Sell |
71,579
-32,491
| -31% | -$108K | ﹤0.01% | 4440 |
|
|
2024
Q1 | $420K | Sell |
104,070
-3,576
| -3% | -$14.4K | ﹤0.01% | 4223 |
|
|
2023
Q4 | $328K | Buy |
107,646
+50,605
| +89% | +$154K | ﹤0.01% | 4275 |
|
|
2023
Q3 | $171K | Sell |
57,041
-41,823
| -42% | -$125K | ﹤0.01% | 4361 |
|
|
2023
Q2 | $370K | Buy |
98,864
+46,051
| +87% | +$172K | ﹤0.01% | 4057 |
|
|
2023
Q1 | $177K | Sell |
52,813
-22,422
| -30% | -$75.1K | ﹤0.01% | 4437 |
|
|
2022
Q4 | $362K | Buy |
75,235
+59,818
| +388% | +$288K | ﹤0.01% | 3937 |
|
|
2022
Q3 | $88K | Buy |
15,417
+4,166
| +37% | +$23.8K | ﹤0.01% | 4757 |
|
|
2022
Q2 | $80K | Sell |
11,251
-17,754
| -61% | -$126K | ﹤0.01% | 4587 |
|
|
2022
Q1 | $209K | Sell |
29,005
-75,716
| -72% | -$546K | ﹤0.01% | 4338 |
|
|
2021
Q4 | $935K | Buy |
104,721
+41,034
| +64% | +$366K | ﹤0.01% | 3494 |
|
|
2021
Q3 | $2.23M | Sell |
63,687
-611,422
| -91% | -$21.4M | ﹤0.01% | 2676 |
|
|
2021
Q2 | $14.5M | Buy |
675,109
+671,483
| +18,519% | +$14.4M | ﹤0.01% | 1291 |
|
|
2021
Q1 | $224K | Sell |
3,626
-6,944
| -66% | -$429K | ﹤0.01% | 4436 |
|
|
2020
Q4 | $442K | Buy |
+10,570
| New | +$442K | ﹤0.01% | 3761 |
|